Synthetic protein could improve diagnosis and treatment of male infertility

NewsGuard 100/100 Score

Queen's University researcher Richard Oko and his co-investigators have come up with a promising method of treating male infertility using a synthetic version of the sperm-originated protein known as PAWP.

They found this protein is sufficient and required to initiate the fertilization process.

Dr. Oko's research promises to diagnose and treat cases of male factor infertility where a patient's sperm is unable to initiate or induce activation of the egg to form an early embryo.

"PAWP is able to induce embryo development in human eggs in a fashion similar to the natural triggering of embryo development by the sperm cell during fertilization," explains Dr. Oko (Biomedical and Molecular Sciences). "Based on our findings, we envision that physicians will be able to improve their diagnosis and treatment of infertility, a problem that affects 10 to 15 per cent of couples worldwide."

The results of this study highlight the potential clinical applications of sperm PAWP as a predictor of infertility treatment. Since most human infertility treatments are now done by injecting a single sperm directly into an egg, supplementation of human sperm with PAWP protein may potentially be used to improve the success rate of infertility treatments in the future.

According to the Centers for Disease Control and Prevention's 2013 Annual Report on Assisted Reproductive Technologies, only about 37 per cent of treatment cycles lead to successful pregnancy. This low success rate may be due to a variety of factors in the male and female including the inability of sperm cell to initiate fertilization and trigger embryo development upon egg entry.

"The results of our study set the stage for further investigation of PAWP protein as a molecular marker for diagnosis and as a factor for improvement of infertility treatments," says Dr. Oko.

Dr. Oko worked with his former PhD student Mahmoud Aarabi and Clifford Librach and Hanna Balakier at the CReATe Fertility Centre in Toronto on this latest research, which was published in the FASEB Journal, the world's most cited biology journal.

Source: Queen's University

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CASGEVY gene therapy eliminates vaso-occlusive crises in sickle cell patients